Skip to content

Text Size: AAA

Strategic Partners

Collaborative Spirit

Amylin places a high value on teamwork and recognizes the enormous benefits of collaborative arrangements. We actively investigate and pursue opportunities that are a good fit with our therapeutic areas we research, as well as our development and commercial capabilities. We seek partners with the same values of integrity, compassion and commitment to develop novel treatments for the patients we aim to serve. For more information about the compounds we are currently developing, please click here to read about our product pipeline.

Our Partners

Amylin has experience forming and operating strategic alliances, ranging from enabling technologies and manufacturing, to full development and commercialization agreements.

Below is a list of Amylin’s current strategic collaborations and partnerships:

 Alkermes Alkermes plc – Amylin worked with Alkermes to develop the first once-weekly treatment for type 2 diabetes using Alkermes’ proprietary technology for long-acting medications.  Amylin and Alkermes continue to develop potential long-acting formulations of exenatide.
Biocon, Limited—In September 2009, Amylin and Biocon entered into an exclusive agreement to jointly develop, commercialize and manufacture a novel peptide therapeutic for the potential treatment of diabetes. Amylin and Biocon will collaborate to develop the therapeutic potential of the compound and share development costs.  Amylin will provide expertise in peptide hormone development as well as metabolic disease therapeutics. Biocon, a biologics innovator and world-class manufacturing expert, will utilize its expertise in recombinant microbial expression to manufacture the compound and also leverage its experience in pre-clinical and clinical development of diabetes products.
Takeda Pharmaceutical Company Limited—In October 2009, Amylin and Takeda entered into a worldwide exclusive license, development and commercialization agreement to co-develop and commercialize pharmaceutical products for the treatment of obesity and related indications.